Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
53 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Biotherapeutics Clinical Site 35
Calgary, Alberta, Canada
- Arcutis Biotherapeutics Clinical Site 37
Surrey, British Columbia, Canada
- Arcutis Biotherapeutics Clinical Site 47
Winnipeg, Manitoba, Canada
- Arcutis Biotherapeutics Clinical Site 43
Fredericton, New Brunswick, Canada
- Arcutis Biotherapeutics Clinical Site 16
London, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 29
Mississauga, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 30
North Bay, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 32
Peterborough, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 36
Waterloo, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 09
Westmount, Quebec, Canada
- Arcutis Biotherapeutics Clinical Site 01
Scottsdale, Arizona, United States
- Arcutis Biotherapeutics Clinical Site 45
Encinitas, California, United States
- Arcutis Biotherapeutics Clinical Site 46
San Diego, California, United States
- Arcutis Biotherapeutics Clinical Site 64
San Diego, California, United States
- Arcutis Biotherapeutics Clinical Site 21
Santa Monica, California, United States
- Arcutis Biotherapeutics Clinical Site 42
Coral Gables, Florida, United States
- Arcutis Biotherapeutics Clinical Site 57
Delray Beach, Florida, United States
- Arcutis Biotherapeutics Clinical Site 33
Largo, Florida, United States
- Arcutis Biotherapeutics Clinical Site 31
North Miami Beach, Florida, United States
- Arcutis Biotherapeutics Clinical Site 65
Sanford, Florida, United States
- Arcutis Biotherapeutics Clinical Site 12
Tampa, Florida, United States
- Arcutis Biotherapeutics Clinical Site 10
Rolling Meadows, Illinois, United States
- Arcutis Biotherapeutics Clinical Site 03
Indianapolis, Indiana, United States
- Arcutis Biotherapeutics Clinical Site 22
Plainfield, Indiana, United States
- Arcutis Biotherapeutics Clinical Site 15
Louisville, Kentucky, United States
- Arcutis Biotherapeutics Clinical Site 04
Lake Charles, Louisiana, United States
- Arcutis Biotherapeutics Clinical Site 02
Rockville, Maryland, United States
- Arcutis Biotherapeutics Clinical Site 28
Rockville, Maryland, United States
- Arcutis Biotherapeutics Clinical Site 40
Clinton Township, Michigan, United States
- Arcutis Biotherapeutics Clinical Site 20
Detroit, Michigan, United States
- Arcutis Biotherapeutics Clinical Site 14
Fridley, Minnesota, United States
- Arcutis Biotherapeutics Clinical Site 44
Saint Joseph, Missouri, United States
- Arcutis Biotherapeutics Clinical Site 19
Reno, Nevada, United States
- Arcutis Biotherapeutics Clinical Site 34
East Windsor, New Jersey, United States
- Arcutis Biotherapeutics Clinical Site 66
New York, New York, United States
- Arcutis Biotherapeutics Clinical Site 63
The Bronx, New York, United States
- Arcutis Biotherapeutics Clinical Site 23
High Point, North Carolina, United States
- Arcutis Biotherapeutics Clinical Site 70
Winston-Salem, North Carolina, United States
- Arcutis Biotherapeutics Clinical Site 18
Bexley, Ohio, United States
- Arcutis Biotherapeutics Clinical Site 71
Portland, Oregon, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Jul 2021
- Primary completion
- 6 Apr 2022
- Completion
- 6 Apr 2022
- Last update posted
- 12 Mar 2024
- Registered enrollment
- 457
- Registry id
- NCT04973228
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.